Thrilled to share findings of a rare pancreatic collision tumor! Check it out below:👇
cureus.com/articles/511766-p…
2
304
Headed to #USCAP2026 for a couple of days of great science, insightful discussions, and connecting with future colleagues in pathology!
See you all there!
@TheUSCAP
#PathX
José Valentín López retweeted
Analysis of B7-H3 in >150,000 cancer samples from >50 histologies. A new therapeutic target is born. Congrats to Carly Miller on her first-author paper. Thanks also to @CarisLife for their collaboration. aacrjournals.org/cancerresco…
Its out! Check out our latest review article “Androgen receptor and estrogen receptor variants in prostate and breast cancers” in the Journal of Steroid Biochemistry and Molecular Biology 🧫 🧬
authors.elsevier.com/a/1izxk…
José Valentín López retweeted
Replying to @UMNChemistry
@UMNChemistry’s summer intramural softball was back after a Covid-hiatus!
Congrats to The Dynamic Scatterers for taking 3rd place! 🙌🏽✨💪🏽
@TLOkeefe12 @RealMMA10 @W_AlvarezReyes @Finetraces786 @caseyh2os + lots of friends!
José Valentín López retweeted
Wonderful presentation by @AlbigesL @GustaveRoussy arguing for doublet v triplet tx. Slides updated to reflect data from @brian_rini @VUMCDiscoveries & @DrTHut @TheUSONetwork presented at #ASCO23 just yesterday (wow!). Come join us in Room E451!
José Valentín López retweeted
Thx to 🌟@OncMedEdCoP team for creating a home for anyone interested in #OncMedEd. ✨All✨ are welcome regardless of profession, training, specialty, or @ASCO membership.
Special thx to @JenSchwartzIUSM and @doctormb1 for our #ASCO23 events!
Join us: surveymonkey.com/r/ASCOMedEd…
#ASCO23 Day 4: Prioritizing and Sequencing Therapy for Advanced Prostate Cancer
4
455
José Valentín López retweeted
Thanks for sharing such an important point! There are so many side-effects that are not seeing! #LCSM #ASCO23
Thank you @bensolomon1 for recognizing that while it’s important to celebrate the wins, it’s critical to remember that tolerable is relative and can change over time for those on chronic treatment.
#LCSM #ASCO23 @EGFRResisters
José Valentín López retweeted
PROSPECT:Can we omit RT in selected patients?
☢️Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer:
☢️Yes! There are no differences regarding DFS, OS, pCR, and locoregional reoccurrence!
@asco @oncoalert #ASCO23 – at Chicago, IL
José Valentín López retweeted
#ASCO23 Plenary session underway with results of the PROSPECT trial
🎗️Compared neoadjuvant CRT vs FOLFOX
🎗️ Non-inferiority DFS was met
🎗️Path CR and QOL similar
🎗️Neoadjuvant FOLFOX, with selective use CRT, is an effective tx for pts with CT2N+, cT3N-, or cT3N+ rectal cancer
Very interesting session on Patient-Centric Clinical Trial Design in GU Cancers happening now at #ASCO23 – at Chicago, IL
1
224
It’s time for the 2023 Medical Student & Resident Abstract Forum.
Come check out my poster (22) in S103.
#ASCO23 @LatinxOncology
5
459
José Valentín López retweeted
ASCO 23 GU cancer highlight @ChrisSweens1 @brian_rini CONTACT-3, THOR, PEACE1, 5 yr KN426 and much more. anchor.fm/the-uromigos/episo…
Getting ready for #ASCO23 day 2 with a 10K run by Lake Michigan.
9
1,012


































